These results indicated that RanBP3 mediates CML proliferation by negatively regulating the tumor growth inhibitor axis TGF-β-SMAD2/3-p21. The gene discussed is SMAD2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.